The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source([1]) . The FDA approved three ...

First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...

Cell and gene therapies (CGTs) are gaining strategic importance across the healthcare landscape, with oncology being the leading therapeutic area followed by cardiovascular and central nervous system ...

A new research project at the Cyprus Institute of Neurology and Genetics (CING) aims to develop a one-time, curative therapy for beta-thalassemia, the most common inherited blood disorder in Cyprus.

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decision ...

The cell and gene therapy industry has achieved breakthroughs once thought impossible, translating novel concepts into real therapeutic options for patients. The FDA has now approved 43 cell and gene ...

Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans laid bare the vaccine skepticism underpinning Robert F. Kennedy Jr.’s new ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...